FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966706677> ?p ?o ?g. }

• W1966706677 endingPage "215" @default.
• W1966706677 startingPage "206" @default.
• W1966706677 abstract "In the present study, we have employed a unique breast cancer cell line (Met-1, which was derived from a high metastatic potential tumor in transgenic mice expressing polyomavirus middle T oncogene) to study the role of CD44 variant isoform(s) in the regulation of metastatic breast tumor cell behavior. The results of reverse transcriptase-polymerase chain reaction, Southern blot, nucleotide sequencing, immunoprecipitation, and immunoblot analyses indicated that these cells express a major CD44 isoform (molecular weight approximately 260 kDa) containing a v3,8-10 exon insertion (designated as CD44v3,8-10). In addition, we have determined that CD44v3,8-10 binds specifically to the cytoskeletal proteins such as ankyrin. Biochemical analyses, using competition binding assays and a synthetic peptide identical to NGGNGTVEDRKPSEL (a sequence located between aa480 and aa494 of CD44v3,8-10) indicate that this 15-amino acid peptide binds specifically to the cytoskeletal protein ankyrin (but not to fodrin or spectrin). This peptide competes effectively for ankyrin binding to CD44v3,8-10. Therefore, we believe that the sequence 480NGGNGTVEDRKPSE494L, located at the cytoplasmic domain of CD44v3,8-10, is required for the ankyrin binding. We have also detected that CD44v3,8-10-containing Met-1 cells are capable of forming membrane spikes or invadopodia structures and undergo active migration processes. Treatments of Met-1 cells with certain agents including anti-CD44v3 antibody, cytochalasin D (a microfilament inhibitor), and W-7 (a calmodulin antagonist), but not colchicine (a microtubule disrupting agent) effectively inhibit invadopodia formation and subsequent tumor cell migration. Further analyses using zymography assays and double immunofluorescence staining indicated that CD44v3,8-10 is closely associated with the active form of matrix metalloproteinase, MMP-9, in a complex within invadopodia structures. These findings suggest that CD44v3,8-10 plays an important role in linking ankyrin to the membrane-associated actomyosin contractile system required for invadopodia formation (coupled with matrix degradation activities) and tumor cell migration during breast cancer progression." @default.
• W1966706677 created "2016-06-24" @default.
• W1966706677 creator A5004049794 @default.
• W1966706677 creator A5011722967 @default.
• W1966706677 creator A5027061409 @default.
• W1966706677 creator A5057272279 @default.
• W1966706677 creator A5066981005 @default.
• W1966706677 creator A5069496915 @default.
• W1966706677 creator A5076510736 @default.
• W1966706677 date "1998-07-01" @default.
• W1966706677 modified "2023-09-23" @default.
• W1966706677 title "CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells" @default.
• W1966706677 cites W1211643602 @default.
• W1966706677 cites W1538880750 @default.
• W1966706677 cites W1553199687 @default.
• W1966706677 cites W1555753650 @default.
• W1966706677 cites W1577146075 @default.
• W1966706677 cites W1593480505 @default.
• W1966706677 cites W1599429565 @default.
• W1966706677 cites W1603789301 @default.
• W1966706677 cites W1606060992 @default.
• W1966706677 cites W1929801845 @default.
• W1966706677 cites W1967265143 @default.
• W1966706677 cites W1989391836 @default.
• W1966706677 cites W1992072758 @default.
• W1966706677 cites W2004203577 @default.
• W1966706677 cites W2005310013 @default.
• W1966706677 cites W2006399167 @default.
• W1966706677 cites W2011069567 @default.
• W1966706677 cites W2011158867 @default.
• W1966706677 cites W2012553828 @default.
• W1966706677 cites W2024602261 @default.
• W1966706677 cites W2026024971 @default.
• W1966706677 cites W2026421217 @default.
• W1966706677 cites W2042171099 @default.
• W1966706677 cites W2052626837 @default.
• W1966706677 cites W2054087284 @default.
• W1966706677 cites W2059946252 @default.
• W1966706677 cites W2065531005 @default.
• W1966706677 cites W2072103796 @default.
• W1966706677 cites W2077003488 @default.
• W1966706677 cites W2095498651 @default.
• W1966706677 cites W2109658199 @default.
• W1966706677 cites W2111449140 @default.
• W1966706677 cites W2135264351 @default.
• W1966706677 cites W2140481166 @default.
• W1966706677 cites W2141418049 @default.
• W1966706677 cites W2143250882 @default.
• W1966706677 cites W2150468943 @default.
• W1966706677 cites W2160905697 @default.
• W1966706677 cites W238469003 @default.
• W1966706677 cites W4211002736 @default.
• W1966706677 cites W4294216491 @default.
• W1966706677 cites W76693565 @default.
• W1966706677 doi "https://doi.org/10.1002/(sici)1097-4652(199807)176:1<206::aid-jcp22>3.0.co;2-3" @default.
• W1966706677 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9618160" @default.
• W1966706677 hasPublicationYear "1998" @default.
• W1966706677 type Work @default.
• W1966706677 sameAs 1966706677 @default.
• W1966706677 citedByCount "259" @default.
• W1966706677 countsByYear W19667066772012 @default.
• W1966706677 countsByYear W19667066772013 @default.
• W1966706677 countsByYear W19667066772014 @default.
• W1966706677 countsByYear W19667066772015 @default.
• W1966706677 countsByYear W19667066772016 @default.
• W1966706677 countsByYear W19667066772017 @default.
• W1966706677 countsByYear W19667066772018 @default.
• W1966706677 countsByYear W19667066772019 @default.
• W1966706677 countsByYear W19667066772020 @default.
• W1966706677 countsByYear W19667066772021 @default.
• W1966706677 countsByYear W19667066772022 @default.
• W1966706677 countsByYear W19667066772023 @default.
• W1966706677 crossrefType "journal-article" @default.
• W1966706677 hasAuthorship W1966706677A5004049794 @default.
• W1966706677 hasAuthorship W1966706677A5011722967 @default.
• W1966706677 hasAuthorship W1966706677A5027061409 @default.
• W1966706677 hasAuthorship W1966706677A5057272279 @default.
• W1966706677 hasAuthorship W1966706677A5066981005 @default.
• W1966706677 hasAuthorship W1966706677A5069496915 @default.
• W1966706677 hasAuthorship W1966706677A5076510736 @default.
• W1966706677 hasConcept C104317684 @default.
• W1966706677 hasConcept C142669718 @default.
• W1966706677 hasConcept C1491633281 @default.
• W1966706677 hasConcept C153911025 @default.
• W1966706677 hasConcept C182800266 @default.
• W1966706677 hasConcept C55493867 @default.
• W1966706677 hasConcept C86803240 @default.
• W1966706677 hasConcept C95444343 @default.
• W1966706677 hasConceptScore W1966706677C104317684 @default.
• W1966706677 hasConceptScore W1966706677C142669718 @default.
• W1966706677 hasConceptScore W1966706677C1491633281 @default.
• W1966706677 hasConceptScore W1966706677C153911025 @default.
• W1966706677 hasConceptScore W1966706677C182800266 @default.
• W1966706677 hasConceptScore W1966706677C55493867 @default.
• W1966706677 hasConceptScore W1966706677C86803240 @default.
• W1966706677 hasConceptScore W1966706677C95444343 @default.
• W1966706677 hasIssue "1" @default.
• W1966706677 hasLocation W19667066771 @default.

• next